Myomectomy Market - By Product (Laparoscopic Power Morcellators, Harmonic Scalpel, Laparoscopic Sealer), By Type (Abdominal Myomectomy, Hysteroscopic Myomectomy, Laparoscopic Myomectomy), By End-use (Hospitals & Clinics, Ambulatory Surgical Centers) – Global Forecast to 2032

Myomectomy Market Size

Myomectomy Market size was valued at USD 681 million in 2022 and is estimated to account for USD 1.6 billion by 2032. Myomectomy is a surgical procedure aimed at removing noncancerous growths known as uterine fibroids from the muscular wall of the uterus. The primary objective of myomectomy is to surgically eliminate the fibroids while preserving the uterus, making it an option for women wishing to retain their fertility or avoid a hysterectomy.
 

Additionally, this procedure can be performed using various methods, including open surgery, laparoscopy, and robotic-assisted surgery. Furthermore, the market is driven by a growing prevalence of uterine fibroids, increasing adoption of advanced surgical technology, rising demand for minimally invasive procedures, and improved healthcare infrastructure, especially in developing countries. These factors collectively contribute to the market expansion.
 

The growing prevalence of uterine fibroids, noncancerous growths in the uterine muscle tissue, is a significant health concern among women, especially those of childbearing age. For instance, according to the Illinois Department of Public Health around 77% women of childbearing age may have uterine fibroids. Additionally, according to the Society for Women’s Health Research report, in the U.S. approximately 26 million women ages 15-50 have uterine fibroids. Therefore, as more women are diagnosed with uterine fibroids, there is an increasing demand for effective treatment options to address the associated symptoms. Furthermore, minimally invasive techniques such as laparoscopy and robotic-assisted surgery are gaining popularity in myomectomy. They involve smaller incisions, reduced blood loss, shorter hospital stays, and faster recovery times compared to open surgery. Thus, patients increasingly prefer myomectomy for less post-operative pain and smaller scars.
 

COVID-19 Impact

The COVID-19 pandemic had a significant negative impact on the myomectomy market and women's healthcare. It disrupted medical services, leading to the postponement of non-urgent procedures and causing delays in diagnosis and treatment. Moreover, supply chain disruptions affected the availability of necessary medical equipment for myomectomy procedures. Furthermore, healthcare facilities redirected resources towards COVID-19 treatment, impacting the attention given to non-urgent medical procedures. As a result, COVID-19 restrained the expansion of the market for myomectomy.
 

Myomectomy Market Trends

Minimally invasive myomectomy techniques have gained popularity due to several advantages over traditional open surgery. Patients undergoing minimally invasive myomectomy procedures typically experience shorter hospital stays and quicker recovery times compared to traditional open surgery. This is especially appealing to individuals desiring to return to their normal activities sooner. Thus, demand for minimally invasive myomectomy procedure is anticipated grow in upcoming years.
 

Furthermore, advances in medical technology have yielded sophisticated surgical devices and equipment for myomectomy, offering surgeons enhanced precision, visualization, and control during procedures. Moreover, this has translated into improved patient outcomes and reduced complications. Therefore, the widespread adoption of robotic-assisted systems and advanced laparoscopic tools has significantly boosted the effectiveness of myomectomy, further stimulating the growth of the market.
 

Myomectomy Market Analysis

The myomectomy market by product is categorized into laparoscopic power morcellators, harmonic scalpel, laparoscopic sealer, and others. The laparoscopic sealer segment expected to witness highest CAGR of 9% in the forecast period. The dominance of the laparoscopic sealer segment is attributed to their minimally invasive approach offers patients smaller incisions, reduced blood loss, shorter hospital stays, and faster recovery, making them increasingly preferred by individuals seeking myomectomy procedures. Moreover, laparoscopic sealers enable precise tissue sealing and cutting, reducing the risk of complications, and enhancing surgical precision.
 

Additionally, improved patient outcomes, including shorter recovery times and reduced post-operative pain, further drives their adoption and market dominance. Therefore, aforementioned factors are projected to impel market demand.
 

Based on type, the myomectomy market is segmented into abdominal myomectomy, hysteroscopic myomectomy and laparoscopic myomectomy. The abdominal myomectomy segment dominated accounted for over 38% business share in the year 2022 and is anticipated to witness highest growth during the forecast period. This is due to a growing number of patient suffering from uterine fibroids, that, in turn increases demands for myomectomy procedures for the treatment.
 

Additionally, this method is accepted as the standard of care for removing fibroids, maintaining the uterus, and giving patients the chance to maintain fertility. It is the only permanent treatment for uterine fibroids. Thus, a rise in myomectomy procedures is anticipated to drive market expansion.
 

Based on end-use, the myomectomy market is segmented into hospitals & clinics, ambulatory surgical centers, and others. The hospitals & clinics segment dominated the market and accounted for over 42% revenue share in the year 2022 and is anticipated to witness highest growth during the forecast period. Hospitals and clinics excel in providing comprehensive healthcare services, equipped with the necessary infrastructure, skilled medical teams, and advanced technology for effective myomectomy procedures.
 

Likewise, patients rely on these healthcare settings for their well-established reputation in delivering high-quality care, leading them to prefer myomectomy surgeries within this trusted environment. Moreover, the presence of expert gynaecologists and surgeons ensures superior patient outcomes and encourages confidence in both providers and patients. Additionally, hospitals and clinics' wide accessibility and role as referral centers expand the availability of myomectomy services to a broader patient base. Thus, aforementioned factors are anticipated to propel the market trends.
 

U.S. myomectomy market accounted for USD 265 million revenue size in 2022 and is predicted to witness substantial market growth over the analysis timeline. The U.S. dominates the market regional analysis due to the high prevalence of uterine fibroids. For instance, according to a report from the Rochester Regional Health approximately 65,000 myomectomy procedures are conducted in the country annually, with majority of these procedures being carried out to address uterine fibroids. Therefore, the high prevalence of uterine fibroids within the U.S. population has significantly contributed to the country's dominance in the market.
 

Furthermore, the country's advanced healthcare infrastructure, access to cutting-edge medical technologies, and strong research and development focus have contributed to its leadership. Additionally, presence of key market players, specialized healthcare facilities, government initiatives, and favourable policies have collectively propelled the adoption of myomectomy procedures in the region.
 

Myomectomy Market Share

Some of the eminent market participants operating in the myomectomy market include:

• Medtronic
• Stryker Corporation
• CONMED Corporation
• INSIGHTEC
• Cooper Surgical Inc
• Hologic, Inc
• Intuitive Surgical
• Karl Storz, B
• Braun Melsungen AG,
• Minerva Surgical Inc,

 These market players are undertaking several growth strategies including partnerships, collaborations, acquisitions & mergers, and new product development & launches to strengthen their product portfolio as well as gain a competitive edge over others.
 

Myomectomy Industry News:

• In October 2021, Hologic, Inc. acquired Bolder Surgical, a privately held U.S. company renowned for its advanced energy vessel sealing surgical devices. This acquisition expanded the company's surgical portfolio and overall elevated its position in the market.
   
• In August 2020, Hologic Inc. acquired Acessa Health Inc., a privately held company that specialized in minimally invasive fibroid therapies. This acquisition enhanced Hologic's product portfolio for fibroid treatment.
   

Myomectomy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product (USD Million & Units)

• Laparoscopic power morcellators
• Harmonic scalpel
• Laparoscopic sealer
• Others

By Type (USD Million)

• Abdominal myomectomy
• Hysteroscopic myomectomy
• Laparoscopic myomectomy

By End-use (USD Million)

• Hospitals & clinics
• Ambulatory surgical centers
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Switzerland
  • The Netherlands
  • Denmark
  • Poland
  • Sweden
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • New Zealand
  • Thailand
  • Vietnam
  • Indonesia
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Turkey